Boreal Capital Management’s Candel Therapeutics CADL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$83.5K Hold
8,000
– – 0.06% 152
2026
Q2
$82.4K Sell
8,000
-8,000
-50% -$60.4K 0.06% 158
2026
Q1
$78.4K Hold
16,000
– – 0.06% 166
2025
Q4
$90.4K Hold
16,000
– – 0.07% 165
2025
Q3
$81.6K Hold
16,000
– – 0.07% 181
2025
Q2
$81K Buy
+16,000
New +$82.4K 0.07% 181

Other funds holding CADL

Boreal Capital Management's CADL Position: Q3 2026 in Review

Boreal Capital Management held its Candel Therapeutics (CADL) position steady in Q3 2026 at 8,000 shares worth $83.5K. The position accounts for 0.06% of the portfolio, ranked #152.

Boreal Capital Management first reported a position in CADL in Q2 2025 and has held it in 6 quarters since. The position peaked at $90.4K in Q4 2025. 141 funds tracked by Wall St. Rank hold CADL as of Q3 2026.

  • Boreal Capital Management held 8,000 shares of Candel Therapeutics worth $83.5K as of Q3 2026.
  • Boreal Capital Management left its Candel Therapeutics share count unchanged in Q3 2026.
  • Candel Therapeutics made up 0.06% of Boreal Capital Management's portfolio in Q3 2026, its #152 holding.
  • Boreal Capital Management first reported a position in Candel Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Boreal Capital Management's Candel Therapeutics position peaked at $90.4K in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.

Based on Boreal Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.